BSD Medical Reports Published Study Demonstrates Improved Survival for Pancreatic Cancer Patients Treated Using the BSD-2000
BSD Medical Corporation (NASDAQ: BSDM), today reported that study results demonstrate a survival benefit, without an increase in toxicity, from the addition of hyperthermia for the treatment of advanced pancreatic cancer patients.







